Purpose: To evaluate outcomes of botulinum toxin (BTX) injection of the inferior oblique (IO) muscle.
Design: Retrospective case series.
Methods: Setting: Single center, ophthalmology department at Boston Children's Hospital.
Study Population: All patients treated with IO muscle injection of BTX (onabotulinumtoxinA) between 2010 and 2020.
Observation Procedure: Sensorimotor evaluations at short-term (<2 months), medium-term (2-4 months), and long-term (≥4 months) intervals.
Outcome Measure: Primary outcomes included median improvement in V-pattern strabismus and primary position hypertropia. Secondary outcomes included IO muscle overaction. Wilcoxon signed-rank tests were performed to identify differences before and after injection.
Results: Record review identified 20 patients with a median age of 4.5 (range, 1-69) years. Median BTX dose injected (31 IO muscles) was 5.0 (range, 3.0-7.0) units. Indications included V-pattern strabismus (N = 8), hypertropia (N = 7), or both (N = 5). Median long-term interval was 6.4 (range, 4.1-26.6) months. Injections were concurrent with treatment of horizontal strabismus in all but 3 cases. Median V-pattern magnitude changed from 10 prism diopters (PD) preoperatively to 0 PD short-term (P = .006) and 3.5 PD long-term (P = .34). Median hypertropia changed from 8.5 PD preoperatively to 1.5 PD short-term (P = .01) and 8 PD long-term (P = .87). Median IO muscle overaction grade improved significantly at short-term (P < .001) and long-term (P = .007) intervals. There were no complications associated with the IO muscle injections.
Conclusions: BTX injection of the IO muscles can be a useful adjunct to the management of V-pattern strabismus. Intervention for primary position hypertropia may be helpful for short-term relief with no expectation of long-term benefit.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajo.2021.07.003 | DOI Listing |
JAMA Otolaryngol Head Neck Surg
January 2025
Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, Paris Saclay University, Paris, France.
Importance: Retrograde cricopharyngeus dysfunction (R-CPD) is an emerging disorder associated with disabling symptoms. The origin of R-CPD remains unknown.
Objective: To investigate the development of symptoms, diagnosis approach, and therapeutic outcomes of R-CPD in patients treated with in-office botulinum toxin injection (BTI) into the cricopharyngeus.
Neurol Sci
January 2025
Department of Neurology, PGIMER, Chandigarh, India.
Background: Non-motor symptoms, including depression, anxiety, sleep disturbances, pain and cognitive dysfunction, are a much more important predictor of quality of life than the severity of dystonia.
Objectives: To assess the effect of Botulinum toxin on non-motor symptoms and quality of life in patients with adult-onset idiopathic focal dystonia.
Methods: Patients aged > 18 years diagnosed with idiopathic focal dystonia were recruited in this longitudinal cohort study.
Facial Plast Surg Aesthet Med
January 2025
Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Selective neurectomy (SN) typically leaves cut nerve endings to be either free-floating or buried in facial muscles. Regenerative peripheral nerve interfaces (RPNIs) use autologous skeletal muscle grafts to provide a nonfacial muscle target for reinnervation. To evaluate the effectiveness of RPNI surgery with SN for improving postoperative facial function through botulinum toxin use and facial movement metrics.
View Article and Find Full Text PDFCurr Rev Clin Exp Pharmacol
January 2025
Section of Legal Medicine, School of Law, University of Camerino, Camerino, 62032, Italy.
Botulinum toxin injections, a popular aesthetic treatment, have over 7.4 million beneficiaries in the U.S.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Purpose: Urinary cytokine changes may serve as biomarkers to assess treatment outcomes for interstitial cystitis/bladder pain syndrome (IC/BPS). This study analyzed the changes in urinary cytokines following various bladder therapies and explored their clinical significance in therapeutic mechanisms.
Methods: A total of 122 patients with IC/BPS treated with platelet-rich plasma (PRP), botulinum toxin-A (BoTN-A), hyaluronic acid (HA), or low-energy shock wave (LESW) were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!